Breast Cancer Trial, Recruiting (NCT05798338)

Breast Cancer Trial, Recruiting NCT05798338 Sponsor: Istituti Clinici Scientifici Maugeri SpA Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05798338 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have signed a consent form agreeing to take part in the study
People who are female
(Group 1) People who have been diagnosed with early-stage breast cancer and whose medical team has recommended surgery
(Group 2) People who have had a clear (normal) mammogram or breast ultrasound within the past 12 months before joining the study
(Group 3) People who have been diagnosed with breast cancer that has spread to other parts of the body (confirmed by lab tests or imaging scans) and whose medical team has recommended chemotherapy

Who may not be able to join:

(Group 1) People whose breast cancer has already spread to distant parts of the body
(Group 1) People who have another type of cancer at the same time
(Group 1) People whose medical team has recommended chemotherapy before surgery
(Group 2) People who have been diagnosed with breast cancer
(Group 2) People who have another type of cancer or a long-term (chronic) illness at the same time
(Group 3) People whose health condition means they are not well enough to receive standard chemotherapy treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0382592272

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05798338

Sponsor: Istituti Clinici Scientifici Maugeri SpA

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: 0382592272

More information: https://clinicaltrials.gov/study/NCT05798338

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have signed a consent form agreeing to take part in the study
People who are female
(Group 1) People who have been diagnosed with early-stage breast cancer and whose medical team has recommended surgery
(Group 2) People who have had a clear (normal) mammogram or breast ultrasound within the past 12 months before joining the study
(Group 3) People who have been diagnosed with breast cancer that has spread to other parts of the body (confirmed by lab tests or imaging scans) and whose medical team has recommended chemotherapy

Who may not be able to join:

(Group 1) People whose breast cancer has already spread to distant parts of the body
(Group 1) People who have another type of cancer at the same time
(Group 1) People whose medical team has recommended chemotherapy before surgery
(Group 2) People who have been diagnosed with breast cancer
(Group 2) People who have another type of cancer or a long-term (chronic) illness at the same time
(Group 3) People whose health condition means they are not well enough to receive standard chemotherapy treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Registry

ClinicalTrials.gov

Start date

1 December 2020

Est. completion

30 September 2023

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

EVs levels in early BC; EVs levels in metastatic BC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov